University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
NCT Number: NCT03924934
This is a prospective multi-center study. Bacterial isolates from hospitalized patients with CA-HRE will be compared to those from hospitalized patients with healthcare-associated HRE (HA-HRE). In addition, community spread of CRE will be determined.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Observational
Chapel Hill, North Carolina, 27599, United States
Patients who are discharged home from the hospital and meet criteria for possible CA-HRE will be recruited. These index participants will be interviewed to determine the epidemiologic network, and will be mailed a monthly BioWipe kit to screen for ongoing HRE intestinal carriage. Contacts of the index participant will also be approached and mailed a BioWipe kit to screen for the presence of HRE and/or carbapenemase gene(s) that were present in the index patient. If this initial sample is negative, the contact is not further interviewed or tested. If the initial screening is positive for the carbapenemase gene of interest, then the contact will be asked to answer the same questions as the index patient and will receive a monthly BioWipe kit. For each positive contact, a second-generation network of contacts will be constructed, who in turn will be approached for screening.
An additional subset of participants, those with CDC-defined HRE isolated during hospitalization who are not discharged home will also be included. All HRE isolates that are isolated from the patient as part of routine clinical care will be sub-cultured and shipped to the central research laboratory. A limited data set will be collected.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Category 1: Patients who live at home and meet the following criteria:
Category 2: Hospitalized patients with CDC-defined HRE isolated during hospitalization who are not discharged home and who meet any of the following criteria:
Category 3: Patients with CDC-defined HRE isolated during a previous hospitalization or outpatient visit who are eventually discharged home and who meet any of the following criteria:
Category 4: Participants who meet the following criteria:
Exclusion criteria
In all categories, participants who meet the following criteria will be excluded:
In category 1, the following are exclusionary:
In addition, in category 1, 3 and 4, who meet the following criteria will be excluded:
Time frame: enrollment - end of study, up to approximately 1 year
Proportion of HRE cases diagnosed in hospitalized patients that are community-associated out of all CRE cases in hospitalized patients
Time frame: enrollment - end of study, up to approximately 1 year
In community contacts of patients discharged from the hospital after HRE diagnosis, the presence or absence of HRE in stool samples will be determined by culture. Then, the total number of community contacts with HRE-positive stool cultures will be divided by the total number of tested community contacts to derive the proportion of community contacts with stool cultures positive for HRE.
University of North Carolina, Chapel Hill
Other
Acronym: COCARE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05055479
Bacterial Infections, Bacterial Infections and Mycoses
Amiens, Picardie, France
View Trial DetailsNCT04528043
Antibiotic Resistant Infection, Bacterial Infections
Vandœuvre-lès-Nancy, Lorraine, France
View Trial DetailsNCT00573235
Bacterial Infections, Bacterial Infections and Mycoses
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07676513
Antibiotic Resistance, Bacterial Infections
Nîmes, Gard, France
View Trial Details